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Hypereosinophilic syndrome (HES) is a rare disorder typically seen in males, aged 20–50, with a predisposition for Caucasians.
It is marked by overproduction of eosinophils (>1,500/μL) and multi-organ system damage due to eosinophilic inﬁltration
and mediator release. There are multiple variants of HES. Cardiac complications are more common in myeloproliferative HES
associated with the FIP1L1-PDGFRα mutation. Sequelae range from acute necrosis and thrombus formation to ﬁbrosis of the
endomyocardium. We describe a young boy who presented with chest pain and dyspnea. A diagnosis of HES was made after
all other etiologies of eosinophilia were excluded. Although he was found to be negative for the FIP1L1-PDGFRα mutation, his
cardiac complications included pericardial eﬀusion and restrictive cardiomyopathy, without myocardial necrosis. Multi-organ
involvement resulted in pericarditis, pleuritis, nephritis, and dermatitis. In this article, we review his case and discuss the known
subtypes of HES, the classic cardiac complications, and available treatment strategies.
Copyright © 2009 Cindy M. Salm et al.ThisisanopenaccessarticledistributedundertheCreativeCommonsAttributionLicense,
which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
1.Introduction
Hypereosinophilic syndrome (HES) is a systemic dis-
ease characterized by eosinophilia and multi-organ dam-
age. Systems involved include the hematologic, cardiovas-
cular, cutaneous, neurologic, pulmonary, gastrointestinal,
splenic, hepatic, and ocular systems. Treatment is directed
at suppression of the eosinophilia and mediator release
[1].
2. History of Present Illness
A previously healthy 13-year-old African American boy
developed erythematous pruritic plaques encircling his
upper arms. The lesions spread over the next 2 days to
his back, chest, face, and legs. After treatment with topical
steroids and antihistamines, the rash resolved, but the pru-
ritis persisted. On day 5, the patient developed shoulder and
knee arthralgias. On day 12, he developed continuous dull
midline chest pains rated 8 out of 10, and dyspnea while
supine. He had fevers on days 15 and 18. On day 21, he
p r e s e n t e dt oa ne m e r g e n c yd e p a r t m e n ta n dw a st r e a t e dw i t h
ibuprofen. The pain persisted, and on day 28, he presented
to Children’s Hospital of Wisconsin Emergency Department
and was admitted.
3.PhysicalExamination
Vital signs on admission were temperature 36.8◦C, heart rate
100beats/minute, blood pressure 102/68mmHg, respiratory
rate 24breaths/minute, and pulse oximetry 99% in room
air. The patient had lost 20pounds over the past month.2 Journal of Allergy
Edemaofthehands,feet,andperiorbitalregionswaspresent.
Breath sounds were decreased and bibasilar rales noted.
Heart rate and rhythm were regular. A cardiac rub was
present. The liver was palpable 2cm below the costal margin
at the right mid-clavicular line. The remainder of the exam
was normal.
4. Laboratoryand Other DiagnosticFindings
Laboratory data included a white blood cell count of
22.4K/uL with 72% segs, 1% bands, 6% lymphocytes, 19%
eosinophils (absolute eosinophil count of 5,600/μL), 1%
monocytes, and 1% basophils. Some eosinophils had more
than 2 lobes. Hemoglobin was 9.9g/dL, and platelets were
446K/uL. Electrolytes, aspartate amino transferase, amino
alanine transferase, and alkaline phosphatase were normal.
Creatinine was 0.9mg/dL, and blood urea nitrogen was
8mg/dL. Erythrocyte sedimentation rate was 48mm/hr, and
C-reactive protein was 16.5mg/dL.
The diﬀerential diagnosis included HES, a drug reaction,
parasitic or fungal infection, Churg Strauss syndrome, acute
eosinophilic leukemia, lymphoma, Gleich syndrome, sys-
temic mastocytosis, adrenal insuﬃciency, and eosinophilic
enteritis. Since HES is a diagnosis of exclusion, the other
disorders were ruled out.
To exclude a drug reaction, ibuprofen, the patient’s
only medication, was held. No subsequent change in the
eosinophilia occurred. Urine drug screen was not per-
formed as clinical suspicion was low. Travel history was
negative. Stool testing for ova and parasites was negative.
HIV, lyme, and toxocara titers were negative. Mycoplasma
polymerasechainreactionwasnegative.Skinbiopsyrevealed
perivascular neutrophilic and eosinophilic inﬁltrate without
ﬁbrinoid necrosis of the vascular wall. Since the patient was
without wheezing or history of asthma, lacked paranasal
sinus abnormalities, and had normal electromyography,
Churg Strauss syndrome was doubtful. Total complement
(CH50),C3,andC4levelswerenormal.Antidoublestranded
deoxyribonucleic acid antibodies, antineutrophilic cytoplas-
mic antibodies, and extractable nuclear antigens panel were
negative. Leukemia, lymphoma, and mastocytosis were not
present as the bone marrow biopsy showed eosinophilia
with some immature forms, but no tumor cells or increased
mast cells. An IgM level was normal and the patient lacked
any known angioedema, making Gleich syndrome unlikely.
IgA, IgG, and IgE were also normal. The patient lacked
any gastrointestinal symptoms, making eosinophilic enteritis
unlikely.
Radiologically, chest X-ray demonstrated a small left-
sided pleural eﬀusion. Echocardiogram revealed a small
pericardial eﬀusion. Chest CT conﬁrmed these ﬁndings, and
also showed enlarged axillary lymph nodes and bibasilar
atelectasis. Ultrasound revealed mildly enlarged kidneys
with hyperechogenicity of the renal cortices. Eosinophils
was not present in the urine, but proteinuria and sterile
pyuria were noted. Coombs test was negative. The FIP1L1-
PDGFRα (F/P) mutation characteristic of myeloproliferative
HES was negative. The CD3-CD4+ T cells characteristic of
lymphoproliferative HES were not present. Serum tryptase
and vitamin B12 levels were normal.
5.ClinicalCourse
The patient’s dyspnea increased, and oxygen dependence
developed during the ﬁrst 2 days of hospitalization. Lasix
was administered. When the diagnosis of HES was made, the
patient was treated with solumedrol 60mg intravenous every
6 hours. In 48 hours, the eosinophil count dropped from
7,100 cells/μL to 100 cells/μL. Over the following 3 weeks,
thedyspneaandoxygenneedgraduallyresolved.Theboywas
transitioned to prednisone 60mg daily.
During the initial 4 weeks of hospitalization, serial
echocardiograms showed enlargement of the pericardial
eﬀusion from small to moderate with myocardial dis-
ease with impaired diastolic function (see Figure 1). Serial
cardiac enzymes remained normal. Endomyocardial ﬁbro-
sis was not present on cardiac MRI (see Figure 2). On
discharge, the patient had neither chest pain nor short-
ness of breath. The absolute eosinophil count remained
normal.
6. Discussion
The diagnosis of HES requires (1) eosinophilia of more than
1,500cells/μL for at least 6months, (2) exclusion of other
causes of eosinophilia, and (3) signs and symptoms of single
or multiple organ involvement [1]. Revising the criteria to
includepatientswhorequiretreatmentpriortosixmonthsof
eosinophilia has been proposed [2]. HES is most commonly
seen in Caucasian males aged 20 to 50 [3–5]. The exact
prevalence of the disease is unknown [3].
Myeloproliferative Hypereosinophilic syndrome (M-
HES) can be diagnosed by detecting a chromosomal aber-
ration on chromosome 4q12 (FIP1L1-PDGFRα mutation),
which results in constitutive tyrosine kinase activity. Patients
with this mutation typically respond well to imatinib
mesylate (Gleevac, Novartis), a tyrosine kinase inhibitor [3].
One in three patients who respond to imatinib mesylate
lacks the F/P mutation, suggesting involvement of other
unidentiﬁed tyrosine kinase genes [6, 7]. In 2004, Klion et
al. considered diagnosis of M-HES when four of eight labo-
ratory criteria listed were met in addition to the criteria that
deﬁne HES: dysplastic eosinophils, increased B12, increased
tryptase,anemia/thrombocytopenia,increasedbonemarrow
cellularity with left shift, myeloﬁbrosis, and dysplastic mast
cells, or megakaryocytes in the bone marrow [8]. Cardiac
manifestations appear to be most common in M-HES and
range from acute necrosis to thrombus formation and
ﬁbrosis [5]. Symptoms and ﬁndings seen during the throm-
botic or ﬁbrotic stage include dyspnea, chest pain, left/right
ventricular failure, and mitral/tricuspid regurgitation [3].
Late manifestations include arrhythmias and chronic heart
failure. Despite the increased risk of thromboembolic disease
in patients with HES, anticoagulant therapy is not formally
recommended, because it has no eﬀect on preventing further
thrombosis [4]. Patients with M-HES, especially those withJournal of Allergy 3
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Figure 1: Echocardiogram showing (a) pericardial eﬀusion and pleural eﬀusion at presentation (from subcostal imaging plane), (b)
progression of pericardial eﬀusion with ﬁbrinous material (from short axis plane), (c) mitral valve Doppler inﬂow signal with reversal
of E and A waves, suggestive of restrictive myocardial disease with impaired diastolic function, (d) impaired diastolic function suggested by





Figure 2: (a) Steady-state free precession cardiac MRI 4 chamber image showing small pericardial eﬀusion, trace pleural eﬀusion, and
posterior lung ﬁeld atelectasis. (b) Delayed enhancement cardiac MRI image (10 minutes postgadolinium infusion) showing no myocardial
delayed enhancement; thus, no ﬁbrosis. Visceral and parietal pericardium noted in white with pericardial eﬀusion appearing dark between
these two layers.
the F/P mutation, possess a particularly poor prognosis
due to their increased risk for cardiac complications and risk
of developing leukemia [7].
Restrictive cardiomyopathy is a rare form of cardiomy-
opathy, accounting for less than 3% of cardiomyopathies
in children [9]. It is characterized by myocardial disease
causing restricted ventricular ﬁlling (diastolic dysfunction)
with preserved systolic function. Primary and secondary
forms have been identiﬁed, with secondary forms more
common in adults and related to inﬁltrative processes,
including amyloidosis, anthracycline cardiomyopathy, radi-
ation toxicity, sarcoidosis, scleroderma, storage diseases,
and HES. In children, restrictive cardiomyopathy is more
often idiopathic, related to anthracycline chemotherapy or
endocardial ﬁbroelastosis,withuptoonethird being familial
[10]. Presenting features of restrictive cardiomyopathy are
similartothosedemonstratedbythispatientwithrespiratory
symptoms, hepatomegaly, and peripheral edema being key
features. Symptoms are related to poor ventricular ﬁlling
resultingfromdecreasedventricularcompliance,whichleads
to elevated central venous pressures, dilated atria and,
if the left ventricle is aﬀected, pulmonary hypertension.
Echocardiography allows initial evaluation of atrial size,
right ventricular and pulmonary pressure, and ventricular
systolic function. Doppler assessments of atrioventricular
valve inﬂow and tissue Doppler methods permit determi-
nation of diastolic function. Using delayed enhancement
pulse sequences after gadolinium injection, cardiac MRI
may be useful for detection of myocardial ﬁbrosis and rare
intracardiac thrombi [11]. Cardiac MRI allows conﬁrmation
of ventricular systolic function using quantitative measures
and can detect pericardial disease to rule out pericardial
constriction [12].
In contrast to M-HES, patients with lymphoprolifera-
tive hypereosinophilic syndrome (L-HES) have less risk of
developing cardiac involvement. Instead, end-organ com-
plications of hypereosinophilia, usually consisting of cuta-
neous manifestations, are present [3]. L-HES is character-
ized by phenotypically aberrant T-cells that overproduce
eosinophilopoietic cytokines, predominately IL-5, but also
IL-4, IL-13, TNF-α, and granulocyte monocyte colony
stimulating factor [7]. The most frequently reported T-cell
phenotype has been CD3-CD4+, but many other variants
exist. Long-term prognosis of L-HES is poor due to the
high risk of developing T-cell lymphoma from malignant
transformation of these aberrant T cells. There is no speciﬁc
treatment for L-HES, though corticosteroids remain the
cornerstone [3]. Emerging research on an anti-interleukin-
5 monoclonal antibody provides hope for corticosteroid-
sparing in these patients. This agent, mepolizumab, has
been studied in HES patients negative for the F/P mutation,
who are dependent on corticosteroids for suppression of
eosinophilia. Concomitant usage of mepolizumab and corti-
costeroids has suppressed eosinophilia while reducing, if not
eliminating, the corticosteroid requirement [7].
7. Followup and Conclusion
Although the patient was tapered oﬀ of prednisone over
the ﬁrst 3 months postdischarge, he demonstrated very
poor followupandmedication compliancein the subsequent
18 months. Serial pulmonary function tests continued to
worsen. The last results, obtained eleven months after
discharge, showed a forced vital capacity 73% of predicted,
forced expiratory volume in one second 62% of predicted,
and forced expiratory ﬂow between 25% and 75% of forced
vital capacity 47% of predicted. His ﬂuticasone inhaler was
increased to three times daily. At his cardiology follow-up
appointment four months after discharge, he was withoutJournal of Allergy 5
cardiovascular complaints, except for mild facial edema.
His echocardiogram showed normal biventricular systolic
function with only minimal septal bounce and no signs of
restrictive cardiomyopathy or residual pericardial eﬀusion.
He was advised to continue aspirin daily and diuretics, as
needed for facial swelling. He failed to attend any further
cardiology appointments.
Most recently, 18months postdischarge, the patient
presented to the Emergency Department with fever, chills,
and malaise. His only reported medication at this time was
aspirin. Vital signs revealed a temperature 37◦C, heart rate
104beats/minute, blood pressure 122/67mmHg, respiratory
rate 36breaths/minute, and pulse oximetry 98% in room air.
Examination was unremarkable. Laboratory data included
a white blood cell count of 17.1K/uL with 54% segs,
4% bands, 15% lymphocytes, 23% eosinophils, and 4%
monocytes. Electrolytes, liver function tests, troponin, and
CPK-MB levels were normal. Electrocardiogram showed
normal sinus rhythm with nonspeciﬁc T wave abnormalities
and borderline prolonged QTc (458msec). Chest X-ray
showed normal cardiac silhouette and pulmonary vascular
markings. Outpatient management with oral prednisone
30mg twice daily for 7 days was advised. The patient failed
to followup.
In this case, a young African American boy with HES
developed rapid pericardial eﬀusion and echocardiographic
evidence of impaired diastolic function with suggestions
of developing restrictive cardiomyopathy over one month.
Cardiac MRI showed no evidence of acute myocardial
necrosis.Thepatientalsohadevidenceofpleuritis,nephritis,
and dermatitis. The patient’s cardiac manifestations, young
age, and race (African American) are all atypical for the non-
FIP1L1-PDGFRαvariantofHES[3–5].Hismarkedresponse
to high dose steroids was initially life-saving, with near
resolution of echocardiographic changes in the immediate
posthospitalization; yet, his subsequent poor followup and
medication noncompliance has made his prognosis grave.
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